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Background: Current evidence about in-vivo effects of HPV cannot definitively clarify the possible negative role of
this worldwide common infection in early embryo development. However in-vitro evidence, seems to underline a
possible negative effect of HPV in increasing blastocyst apoptosis and in reducing the endometrial implantation of
trophoblastic cells. On these bases we believe that a new scientific approach is necessary to better understand the
real role of male and female HPV infection in infertility and early pregnancy development.
Methods: English literature review of manuscripts focused on HPV infection and human reproduction was
conducted. We performed a critical analysis of evidence and possible bias affecting both in-vivo and in-vitro studies
regarding this topic.
Results: The biggest limitation of the in-vivo studies is due to the inappropriate timing of HPV effects evaluation
since evidence about in-vitro studies strongly suggests that a large part of HPV negative effects occurs during a
very early stage of embryo development. All the efforts of the scientific community to investigate the real role of
HPV in human reproduction disorders cannot underestimate the severe BIAS of actual evidence in postulating new
hypothesis and research projects which are fundamental to clarify if HPV may be associated with unexplained
couples infertility and early miscarriages.
Conclusions: If the relationship between HPV gametes infection and early human reproduction step impairment
will be confirmed, the HPV male and couple vaccination may represent a reliable option to improve fertility in
some couples affected by infertility actually classified as “idiopathic” but maybe linked to HPV infection.
Keywords: HPV infection, Human reproduction, Sperm infection, Couple infertility, Early miscarriage, Study BIAS,
Embryo development, Blastocyst, Trophoblastic cellsBackground
Starting from our recent systematic literature review
about “Male and Couple Fertility Impairment due to
HPV-DNA Sperm Infection” we focused our attention on
the controversies concerning HPV infection in human
reproduction impairment [1]. Current evidence about in-
vivo effects of HPV cannot definitively clarify the possible
negative role of this worldwide common infection in early
embryo development [2-6]. However, in-vitro evidence* Correspondence: ginecologia_padova@libero.it
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unless otherwise stated.seems to underline a possible negative effect of HPV in in-
creasing blastocyst apoptosis and in reducing the endo-
metrial implantation of trophoblastic cells [7-15]. Despite
Matovina et al. detected the HPV-DNA in miscarriages
specimens without any significant association [16], in our
knowledge only two clinical studies demonstrated a pos-
sible relationship between HPV and early pregnancy loss.
Hermonat et al. comparing the prevalence of HPV in sam-
ples from spontaneous miscarriages and elective abortions
found that 15 of the 25 spontaneous samples (60%) were
positive for HPV-DNA sequences compared to only 3 of
the 15 elective samples (20%) [2]. The higher percentagel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Noventa et al. Reproductive Biology and Endocrinology 2014, 12:48 Page 2 of 4
http://www.rbej.com/content/12/1/48of HPV-DNA detection, if compared to voluntary abor-
tions, lead the Authors to consider HPV as one of the pos-
sible etiologic agents responsible for early pregnancy loss.
Perino et al., on a total of 199 couples undergoing to IVF
cycles (in-vitro fertilization), found an increased risk of
pregnancy loss both in case of male sperm infection
(66.7% versus 15%) and of female cervical infection (40%
versus 13.7%) [3].
Anyway the interesting results of Perino et al. should
be interpreted with caution since several Authors re-
ported approximately 24% of cervical HPV-DNA detec-
tion in women with ongoing pregnancy [17,18].
Other 3 available studies (other than Matovina et al.
[16]) failed to find a possible correlation between HPV in-
fection and early miscarriages [4-6]. Skoczynski et al., on a
total of 129 women, found the HPV-DNA in 17.7% of
spontaneous miscarriages samples and in 24.4% of pla-
centa from term deliveries [4]. Also Conde-Ferraez et al.,
comparing 127 women with spontaneous abortion attend-
ing for curettage and 127 pregnant women at-term, found
an HPV cervical prevalence of 24.4% and 15.2% respect-
ively without significant correlation between HPV infec-
tion and pregnancy loss [5]. Ticconi et al., analyzing
retrospectively 49 cases of women with unexplained re-
current miscarriages and 475 healthy controls, found a
cervical HPV prevalence of 26.53% in cases (13 of 49) and
61.89% in controls (294 of 475) confirming the absence of
a causal association between HPV and miscarriages [6].
Discussion
We believe that all the in-vivo studies conducted till
now (except for the perspective one of Perino et al.) are
affected by different BIAS which probably led to confu-
sion in considering the final results. The first possible
BIAS is related to the HPV types detected: all the cited
studies focused in particular on high-risk (Hr) genotype
16 and 18 extending the search only to few other Hr-
genotypes or low risk HPV 6/11. The second BIAS is re-
lated to the sample detection methods of HPV presence
which did not permit to rule out the possible contami-
nations derived by the passage through the genital tract.
Adjunctively the study by Conde-Ferraez et al. and Tic-
coni et al., focusing only on cervical HPV detection, did
not consider the possible BIAS related to the viral clear-
ance (at time of cervical sample the patients may have
already cleared the virus) which can lead to an under-
estimation of the problem [19]. The third BIAS is related
to the fact that all these studies are built without consid-
ering the new inputs provided by recent in-vitro evi-
dence which demonstrated that HPV sperm infection
seems to have a possible role in adverse blastocyst devel-
opment [7,14]. In particular it has been demonstrated
that the spermatozoa is a vector for HPV transmission
into fertilized oocytes and that the infected zygote (if theoocyte is fertilized) is able to perpetuate the viral gen-
ome expression at blastocyst stage and subsequently in
trophoblastic cells [7,13,20].
On these bases we believe that a new scientific ap-
proach is necessary to better understand the real role of
male and female HPV infection in early pregnancy de-
velopment and infertility. We think that the recent in-
vitro evidence on this field represents a good starting
point to plan new perspective studies and to avoid the
above mentioned BIAS.
Yet in 1996 Cabrera et al. in a murine experimental
study demonstrated that spermatozoa carrying HPV-16
and −18 viral genome can be transfected into a mouse
blastocyst with viral DNA localization both in the inner
cells mass and trophoblastic cells [14]. The consequences
of this possible “colonization” were subsequently evaluated
by different Authors who confirmed the possible adverse
effects of HPV at different steps of human embryo devel-
opment. Calinisan et al. found that mouse blastocysts in-
cubated with HPV-DNA-16 fragments showed an
increased rate of DNA fragmentation and apoptosis [15].
This interesting result was subsequently confirmed and
deepen by Henneberg et al. who defined the exact timing
of HPV embryo impairment. In particular the Author
showed how HPV-16 and −18 are able to inhibit the em-
bryo development only at 2 cells stage (but not at 4–8
cells stage) with a peak percentage of about 30% after
HPV-16 exposure and a major inhibition of blastocyst
hatching process after HPV-18 exposure [10]. Different
Authors demonstrated also the negative effect of HPV
presence in trophoblastic cells which could result in ab-
normal placentation and maybe in early pregnancy loss.
You et al. demonstrated that trophoblastic cells, like squa-
mous epithelium, are broadly permissive for HPV showing
some similarities in the gene expression repertoire be-
tween these two cells. She found an active viral genome
expression (both early and late genes) in 3A tropho-
blastic cells previously cultured with HPV 16,18,11,31.
Moreover she found, in different in-vitro studies, that
HPV-31 infection and HPV-16 E6 and E7 oncogenes
caused both a decrease in 3A trophoblastic cells num-
ber and a low trophoblast-endometrial cells adhesion in
the first week after the exposure [12,13]. The evidence
that HPV-16 is able to complete its life cycle in tropho-
blastic cells was previously reported by Liu et al. [21].
These findings provided to expand HPV biology, to
support the hypothesis of a possible link between HPV
and some spontaneous abortions, and to search a new
technology for studying HPV.
These effects were also confirmed by Gomez et al.
who found a 3- to 6- fold greater rate of apoptosis in
trophoblastic cells transfected with a plasmid contain-
ing the entire HPV-16 genome and a progressive de-
crease of trophoblast invasion ability (25.2-57.6%) from
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tive controls [9]. Also Hong et al. showed a similar
trend with a reduction both of implantation rate (less
37.2%) and of migratory/invasive activity in embryos
exposed to HPV-16 [7].
The reasons which could explain the reduction of inva-
siveness of trophoblastic cells were suggested by Boulenouar
et al. who found a down-regulation of E-cadherin (a funda-
mental protein for an adequate cell-to-cell adhesion) in
trophoblastic cells expressing HPV-16 viral genome [8].
Although all the considered studies have important
limitations (which should not be underestimated) linked
to the in-vitro artificial and experimental conditions,
most of the analyzed data suggested a possible adverse
effect of HPV infection in early pregnancy development
and maybe in idiopathic couple infertility. The demon-
stration that also the spermatozoa can act as a vector of
HPV viral genome into oocyte [20] force the scientific
community to understand what may be the clinical impli-
cation of this discovery. In fact, in 2010 Syrjanen reported
that peri-conceptual transmission could theoretically
occur via infected oocyte or spermatozoa [22]. So, al-
though currently no studies exist on HPV detection in oo-
cytes, theoretically, subsequent virus transmission might
originate from the embryos soon after fertilization (such
as via spermatozoa carrier) [20,22].
This fact acquires an even greater importance since
the recent estimated prevalence of HPV sperm infection
is about 10% (95% CI:7–14%) in general male population
and 16% (95% CI:10–23%) in men affected by unex-
plained infertility [23].
So, focusing the investigations on HPV implications in
human reproduction, it is mandatory to shift the older
concept of infection with female gender target (i.e. onco-
logic risk in infected women respect to men) and to start
in considering the HPV infection as a couple or, even
better, a men problem.
In agreement with this new conception, it is intuitive
that all the available in-vivo studies are not useful to
completely understand the HPV exact role in human in-
fertility because study methods, patients selection and
idea conception seem to be inadequate.
The biggest limitation of the in-vivo studies is due to the
inappropriate timing of HPV effects evaluation since evi-
dence about in-vitro studies strongly suggests that a large
part of HPV negative effects are carried out during a very
early stage of embryo development (within the first two
weeks after conception). These effects are very difficult
to be demonstrated by clinical studies since it is possible
to detect a causal-effects ratio on human reproduction
only starting from the third week after conception (five
week of amenorrhea). In this way all clinical studies lose
a large part of negative effects demonstrated by in-vitro
experimental studies.Anyway clinical evidence can elucidate the conse-
quences of HPV in late embryos development and preg-
nancy evolution. The detection of HPV in the placental
tissue [24] lead to speculate about its possible role in ad-
verse pregnancy outcomes since only few recent studies
find an association between viral detection, placental ab-
normalities and preterm delivery [9,25,26]. Despite the
increasing evidence of HPV vertical transmission [27,28],
this route is regarded as less clinically important because
of the detections of transient HPV-DNA. However, re-
cent studies have provided clear evidence of papillomavi-
rus productive infection in lymphocytes and placenta
[29]. Furthermore, a model of papillomavirus latency has
been recently proposed that could explain the failure or
transience in HPV detection observed in some infected
infants. This new evidence of hematogeneous and verti-
cal spread of HPV suggests that these modes of trans-
mission should be investigated in greater detail to obtain
a better understanding of the infection and a fuller
awareness of the preventive measures that can be taken
against HPV-related diseases [30].
Conclusions
In conclusion all the efforts of the scientific community to
investigate the real role of HPV in human reproduction
disorders cannot underestimate the severe BIAS of previ-
ous evidence in postulating new hypothesis and research
projects. Even if the choice of more appropriate laboratory
techniques (ISH rather than PCR) could partially solve the
BIAS linked to potential contamination of specimen, shift-
ing the attention on men and couples rather than only on
women represent a first step to solve the dilemma. As sug-
gestion to Clinicians interested in the topic we invite to
focus the attention on idiopathic infertile couples under-
going ART cycles, theoretically the most appropriate co-
hort to plan both in-vitro and in-vivo further studies.
We must definitively understand if the hypothesized ad-
verse effects of HPV in human reproduction is only a sup-
position derived from a “inconclusive” scientific speculation
or if we are faced to a new important discovery which can
potentially clarify the exact mechanism of some cases of
unexplained couples infertility and of early miscarriages
linked to HPV infection.
So If the suspected HPV role in early human reproduction
impairment will be confirmed by well conducted further
studies, the couple vaccination before attempting both
spontaneous and assisted pregnancy could be a reliable
and effective tool [31].
The rationale for proposing the use of HPV vaccin-
ation (Gardasil® or Cervarix®) in couple attempting ART
cycle is based on the evidence that in man the HPV
sperm infection seems associated with some spermatic
parameters impairment [1] and in women HPV vaccin-
ation strength the immunological response to the HPV
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tion and superinfection by a different hr-HPV and lr-
HPV genotypes [31]. As theoretical assumption, couple
vaccination may potentially reduce some “undetected
early miscarriage” actually erroneous considered as ART
failure (lack of embryos implantation) increasing the
pregnancy rate (first aim of ART procedures).
If in infertile couple the fertility rate will result in-
creased after vaccination, this can be considered an in-
direct confirmation of our hypothesis and a suggestion
to start more appropriate in-vitro and epidemiological
studies on this field.
Improvement in the knowledge of HPV-DNA sperm
infection mechanisms, timing, and link to fertility im-
pairment may explain some of the actual “idiopathic”
male and couple infertility.Competing interests
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